menu
    • menu

    Company profile for Pharmathen SA

    NEW Drugs in Dev: 3
    Pharmathen SA-PSE
    News
    Wise Equity-Backed Ntc, Acquires Pharmathen's Ophthalmology Unit

    10 Dec 2025

    // PR NEWSWIRE

    Pharmathen Achieves EcoVadis Silver Medal for Sustainability 202

    11 Oct 2025

    // PRESS RELEASE

    Pharmathen announces John Nason as incoming Group CEO

    17 Jul 2025

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Pharmathen

    Contact Supplier

    Website

    DCAT Week

    Lotte New York Palace

    Book a meeting

    envelop Contact Supplier

    Latest Content

    https://www.youtube.com/embed/HVNalSClOPQ

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

    Related CompaniesRelated Companies

    About

    Pharmathen, established in 1969, has emerged as a leading in-house development partner in Europe. It specializes in the development, registration, manufacturing & life-cycle management of complex pharmaceutical technologies & generic formulations. With a portfolio of over 100 products, Pharmathen serves over 250 clients across 80 countries. It’s pipeline includes advanced long-acting injectables, sustained-release formulations & preservative-free ophthalmics manufactured in USFDA & EU-approved facilities. Pharmathen’s core technology platforms, including microspheres, nanosuspensions & nanogels, are used to develop long-acting therapies.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Pharmathen SAGreece Flag
    Country
    Country
    Greece
    Address
    Address
    44, Kifissias Avenue, 15125 Marousi Attica
    Telephone
    Telephone
    +30 2106604300
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.pharmathen.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/pharmathen/
    youtube
    YouTube
    http://www.youtube.com/@Pharmathen
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    dcat-week-png-51097.png

    DCAT Week

    Lotte New York Palace

    envelop Contact Supplier

    DCAT Week

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/pharmathen-sa-party-content-89593.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/pharmathen-sa-party-content-74862.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    API Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/pharmathen-sa-party-content-97285.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    FDF Product List 2025 USA

    read-more

      https://www.pharmacompass.com/pdf/party/content/pharmathen-sa-party-content-95847.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    FDF Product List 2025 Global

    read-more

      https://www.pharmacompass.com/pdf/party/content/pharmathen-sa-party-content-22500.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/pharmathen-sa-party-content-27633.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Every year, the US Food and Drug Administration (FDA) publishes the user fee amounts it will collect from manufacturers of pharmaceuticals, generic drugs, biosimilars and medical devices in the coming financial year. The fee for fiscal year 2025 under the Generic Drug User Fee Act (GDUFA) was published on July 31, 2024.The GDUFA, established in 2012, authorizes FDA to assess and collect fees from drug manufacturers to expedite the delivery of safe, high-quality, and affordable generic drugs to the American public.The FDA’s facility payments list under GDUFA reveals that as of November 14, 2024, 1,397 facilities had paid their registration fees for financial year 2025. Of these facilities, 707 or 50.6 percent are active pharmaceutical ingredients (API) facilities, 405 or 29 percent are finished dosage forms (FDF) facilities, 69 (4.9 percent) are facilities that produce both APIs and FDFs, and 216 (15.5 percent) are contract manufacturing services (CMO) sites.Teva Pharmaceuticals, with 29 facility registrations, led the list of companies, followed by Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories. Fiscal year Facility Registrations 2016 1,425 2017 1,442 2018 1,269 2019 1,286 2020 1,300 2021 1,340 2022 1,385 2023 1,394 2024 1,447 2025 1,397  Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available)India continues to lead with 396 facilities, US and China follow India maintains its dominance in total facility registrations with the FDA, registering 396 facilities for FY2025. This includes 214 API facilities, 135 FDF facilities, 21 facilities engaged in both API and FDF activities, and 26 CMO facilities.The United States holds the second position with 328 facilities, while China strengthened its third position with 197 facilities.With 214 API facilities, India continues to have the largest share of API manufacturing sites, outmatching the combined total of China (128) and the US (83), which together account for 211 facilities. Among European manufacturers, Italy leads with 59 API manufacturing sites, followed by Spain (30) and Germany (25).The US has maintained its lead in FDF facilities with 143 sites, followed closely by India with 135 sites and China with 45 sites. Country API FDF Both CMO Total India 214 135 21 26 396 US 83 143 13 89 328 China 128 45 12 12 197 Italy 59 3 2 19 83 Germany 25 4 1 15 45 Spain 30 9 1 4 44 Canada 7 17   13 37 Taiwan 9 6 5 4 24 Switzerland 15 4   4 23 France 16     6 22 Japan 18   1   19 United Kingdom 12 1   2 15 Mexico 9 1   1 11 Ireland 5 5   1 11   Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) GDUFA III user fee rates increase across categories for FY25The GDUFA, which was reauthorized on September 30, 2022 (as GDUFA III), continues with provisions that will last until September 30, 2027. In July 2024, the FDA published updated user fee rates for FY2025.The facility fees have seen increases across all categories. API facility fees increased by 3 percent for domestic sites (to US$ 41,580) and 2 percent for foreign sites (to US$ 56,580). FDF facility fees rose by 5 percent for both domestic (to US$ 231,952) and foreign sites (to US$ 246,952). CMO facility fees increased by 5 percent for domestic sites (to US$ 55,668) and 4 percent for foreign sites (to US$ 70,668).Additionally, the fee for large-, medium- and small-sized drug applicants has increased by over 9 percent, compared to the 7 percent increase seen in 2023. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) China leads new facility registrations as FDA records 41 new units in FY25Out of the total 1,397 facilities registered for FY2025, 41 were new registrations (going by Facility FDA Establishment Identifier numbers). China led the way with 13 new facilities, followed closely by India with 11 new facilities, while the US secured the third position with eight new facilities.The new registrations included 15 API facilities, 13 CMO facilities, 12 FDF facilities, and one facility engaged in both API and FDF activities. Chinese companies dominated the new FDF registrations with six facilities: Chengdu Shuode Pharma, Chengdu Suncadia Medicine, Cipla (Jiangsu), GE Healthcare (Shanghai), Luoxin Aurovitas Pharma (Chengdu), and Zhejiang Xianju Pharma.India added two new FDF facilities through Eugia Steriles and Zydus Pharma. Malaysia registered two FDF facilities through Novugen Pharma and Novugen Oncology, while Turkey’s Insud Pharma subsidiary Exeltis and US’ RK Pharma registered one FDF facility each.The 13 new CMO facilities included, Acme Generics, Emcure, Esjay Pharma, Fordoz Pharma, Fourrts Laboratories, Laboratoires KABS, PharmaMax, Quality Packaging Specialists International, Ritsa Pharma, Shanghai Aucyun Pharma, Sichuan Huiyu Pharma, Taejoon Pharm, and Tubilux Pharma.In the API category, the 15 new registrations included Acharya Chemicals, Hainan Poly Pharma, CBL Patras, EUROAPI, Hybio Pharma, Medilux Laboratories, Metrochem API, Purolite, Chengdu Easton Biopharma, Sionc Pharma, Smithfield Bioscience, Xttrium Laboratories, Zhejiang Hengkang Pharma, Moehs Iberica and Shilpa Pharma. Armstrong Pharmaceuticals registered the sole facility for both APIs and FDFs.So far, 92 facilities have not renewed their registration. Among these was a facility owned by Sandoz subsidiary Eon Labs in Wilson, North Carolina (US), which is permanently closed. In fact, the geographical distribution of non-renewals shows that 30 facilities were from the US, while India and China accounted for 14 and nine non-renewals respectively. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) Our viewThe FY 2025 GDUFA facility registration data indicates a continued strong presence of Indian manufacturers in the US generic drug market, particularly in API production. However, China's leadership in new facility registrations, especially in FDF manufacturing, suggests that the global generic drug supply chain landscape may evolve considerably in the coming years. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 15546

    https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities

    #PharmaFlow by PHARMACOMPASS
    21 Nov 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Wise Equity-Backed Ntc, Acquires Pharmathen's Ophthalmology Unit
    Wise Equity-Backed Ntc, Acquires Pharmathen's Ophthalmology Unit

    10 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ntc-backed-by-wise-equity-completes-the-acquisition-of-pharmathens-ophthalmology-business-302634307.html

    PR NEWSWIRE
    10 Dec 2025
    Share Share
    Pharmathen Achieves EcoVadis Silver Medal for Sustainability 202
    Pharmathen Achieves EcoVadis Silver Medal for Sustainability 202

    11 Oct 2025

    // PRESS RELEASE

    https://www.pharmathen.com/Pharmathen-Achieves-EcoVadis-Silver-Medal-for-Sustainability-in-2025

    PRESS RELEASE
    11 Oct 2025
    Share Share
    Pharmathen announces John Nason as incoming Group CEO
    Pharmathen announces John Nason as incoming Group CEO

    17 Jul 2025

    // PRESS RELEASE

    https://www.pharmathen.com/Pharmathen-announces-John-Nason-as-incoming-Group-CEO-succeeding-Dimitris-Kadis

    PRESS RELEASE
    17 Jul 2025
    Share Share
    Pharmathen supports Ronald McDonald House Charities Hellas
    Pharmathen supports Ronald McDonald House Charities Hellas

    11 Jul 2025

    // PRESS RELEASE

    https://www.pharmathen.com/Pharmathen-supports-Ronald-McDonald-House-Charities-Hellas-for-the-second-consecutive-year

    PRESS RELEASE
    11 Jul 2025
    Share Share
    ADVANZ PHARMA and Pharmathen Expand Strategic Partnership
    ADVANZ PHARMA and Pharmathen Expand Strategic Partnership

    15 May 2025

    // PRESS RELEASE

    https://www.pharmathen.com/Advanz-pharma-and-Pharmathen-expand-strategic-partnership

    PRESS RELEASE
    15 May 2025
    Share Share
    CNS link-up between Neuraxpharm and Pharmathen
    CNS link-up between Neuraxpharm and Pharmathen

    13 Dec 2024

    // PRESS RELEASE

    https://www.pharmathen.com/Neuraxpharm-and-Pharmathen-enter-into-strategic-co-development-agreement

    PRESS RELEASE
    13 Dec 2024
    Share Share

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

    Neuraxpharm and Pharmathen Enter into Agreement to Develop Long-acting Therapies

    Details:

    The agreement aims to co-develop new long-acting injectable therapies within the psychiatry field under Pharmathen’s long-acting therapeutic technologies (LATT) program.


    Lead Product(s): Undisclosed

    Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

    Study Phase: UndisclosedProduct Type: Undisclosed

    Sponsor: Neuraxpharm

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement December 12, 2024

    Pharmathen

    01

    Pharmathen SA

    Greece
    arrow
    DCAT Week
    Lotte New York Palace
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Undisclosed

    Partner/Sponsor/Collaborator : Neuraxpharm

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Neuraxpharm and Pharmathen Enter into Agreement to Develop Long-acting Therapies

    Details : The agreement aims to co-develop new long-acting injectable therapies within the psychiatry field under Pharmathen’s long-acting therapeutic technologies (LATT) program.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Undisclosed

    December 12, 2024

    Pharmathen

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

    Partners Group to Acquire Pharmathen, a Leading European Pharmaceutical Company, from BC Partners

    Details:

    Partners Group to Acquire Pharmathen, a Leading European Pharmaceutical Company, from BC Partners


    Lead Product(s): Undisclosed

    Therapeutic Area: Ophthalmology Brand Name: Undisclosed

    Study Phase: UndisclosedProduct Type: Undisclosed

    Sponsor: Partners Group

    Deal Size: $1,900.0 million Upfront Cash: Undisclosed

    Deal Type: Acquisition July 19, 2021

    Pharmathen

    02

    Pharmathen SA

    Greece
    arrow
    DCAT Week
    Lotte New York Palace
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Ophthalmology

    Highest Development Status : Undisclosed

    Partner/Sponsor/Collaborator : Partners Group

    Deal Size : $1,900.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Partners Group to Acquire Pharmathen, a Leading European Pharmaceutical Company, from BC Partners

    Details : Partners Group to Acquire Pharmathen, a Leading European Pharmaceutical Company, from BC Partners

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Undisclosed

    July 19, 2021

    Pharmathen

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

    A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for I...

    Details:

    Paliperidone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Schizophrenia.


    Lead Product(s): Paliperidone

    Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

    Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 07, 2018

    Pharmathen

    03

    Pharmathen SA

    Greece
    arrow
    DCAT Week
    Lotte New York Palace
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

    Lead Product(s) : Paliperidone

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 ...

    Details : Paliperidone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Schizophrenia.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    February 07, 2018

    Pharmathen

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

    Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects

    Details:

    MDX1303 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Anthrax.


    Lead Product(s): MDX1303

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Undisclosed

    Sponsor: Department of Health and Human Services | National Institute of Allergy and Infectious Diseases | National Institutes of Health

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 23, 2010

    Pharmathen

    04

    Pharmathen SA

    Greece
    arrow
    DCAT Week
    Lotte New York Palace
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

    Lead Product(s) : MDX1303

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Department of Health and Human Services | National Institute of Allergy and Infectious Diseases | National Institutes of Health

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Norma...

    Details : MDX1303 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Anthrax.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Inapplicable

    December 23, 2010

    Pharmathen

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

    Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use

    Details:

    Valortim is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hypersensitivity.


    Lead Product(s): Valortim

    Therapeutic Area: Immunology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Antibody, Unconjugated

    Sponsor: National Institute of Allergy and Infectious Diseases | National Institutes of Health

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 17, 2010

    Pharmathen

    05

    Pharmathen SA

    Greece
    arrow
    DCAT Week
    Lotte New York Palace
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

    Lead Product(s) : Valortim

    Therapeutic Area : Immunology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : National Institute of Allergy and Infectious Diseases | National Institutes of Health

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use

    Details : Valortim is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hypersensitivity.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    September 17, 2010

    Pharmathen

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Contact Pharmathen SA and get a quotation

    Pharmathen SA is a supplier offers 22 products (APIs, Excipients or Intermediates).

    Find a price of Aprepitant bulk with DMF offered by Pharmathen SA

    Find a price of Brinzolamide bulk with DMF offered by Pharmathen SA

    Find a price of Fluvastatin Sodium bulk with DMF offered by Pharmathen SA

    Find a price of Paliperidone bulk with DMF offered by Pharmathen SA

    Find a price of Valganciclovir Hydrochloride bulk with DMF offered by Pharmathen SA

    Find a price of Voriconazole bulk with DMF offered by Pharmathen SA

    Find a price of Aripiprazole bulk offered by Pharmathen SA

    Find a price of Aripiprazole Lauroxil bulk offered by Pharmathen SA

    Find a price of Clopidogrel Besylate bulk offered by Pharmathen SA

    Find a price of Dimethyl Fumarate bulk offered by Pharmathen SA

    Find a price of Febuxostat bulk offered by Pharmathen SA

    Find a price of Ibandronate Sodium bulk offered by Pharmathen SA

    Find a price of Iron Sucrose bulk offered by Pharmathen SA

    Find a price of Linezolid bulk offered by Pharmathen SA

    Find a price of Nusinersen bulk offered by Pharmathen SA

    Find a price of Paliperidone Palmitate bulk offered by Pharmathen SA

    Find a price of Pregabalin bulk offered by Pharmathen SA

    Find a price of Ropinirole Hydrochloride bulk offered by Pharmathen SA

    Find a price of Tapentadol bulk offered by Pharmathen SA

    Find a price of Tolterodine Tartrate bulk offered by Pharmathen SA

    Find a price of Vildagliptin bulk offered by Pharmathen SA

    Find a price of Vitamin D3 bulk offered by Pharmathen SA

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search